Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.290
-0.100 (-2.95%)
Feb 21, 2025, 4:00 PM EST - Market closed
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
33.36M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
GRCE News
- 10 days ago - Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update - GlobeNewsWire
- 12 days ago - Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study - Benzinga
- 13 days ago - Grace Therapeutics Announces Private Placement Financing of up to $30 Million - GlobeNewsWire
- 13 days ago - Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH - GlobeNewsWire
- 6 weeks ago - Grace Therapeutics to Participate in Upcoming Investor Events January 2025 - GlobeNewsWire
- 4 months ago - Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewsWire
- 5 months ago - Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 - GlobeNewsWire
- 6 months ago - Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire